1. Home
  2. IRD vs MTEN Comparison

IRD vs MTEN Comparison

Compare IRD & MTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • MTEN
  • Stock Information
  • Founded
  • IRD 2018
  • MTEN 2015
  • Country
  • IRD United States
  • MTEN China
  • Employees
  • IRD N/A
  • MTEN N/A
  • Industry
  • IRD
  • MTEN Building Products
  • Sector
  • IRD
  • MTEN Industrials
  • Exchange
  • IRD NYSE
  • MTEN Nasdaq
  • Market Cap
  • IRD 36.0M
  • MTEN 36.6M
  • IPO Year
  • IRD N/A
  • MTEN 2024
  • Fundamental
  • Price
  • IRD $1.13
  • MTEN $5.46
  • Analyst Decision
  • IRD Strong Buy
  • MTEN
  • Analyst Count
  • IRD 1
  • MTEN 0
  • Target Price
  • IRD $8.00
  • MTEN N/A
  • AVG Volume (30 Days)
  • IRD 141.3K
  • MTEN 104.9K
  • Earning Date
  • IRD 02-19-2025
  • MTEN 10-18-2024
  • Dividend Yield
  • IRD N/A
  • MTEN N/A
  • EPS Growth
  • IRD N/A
  • MTEN N/A
  • EPS
  • IRD N/A
  • MTEN 0.13
  • Revenue
  • IRD $8,381,000.00
  • MTEN $9,136,855.00
  • Revenue This Year
  • IRD N/A
  • MTEN N/A
  • Revenue Next Year
  • IRD $29.37
  • MTEN N/A
  • P/E Ratio
  • IRD N/A
  • MTEN $39.88
  • Revenue Growth
  • IRD N/A
  • MTEN 18.30
  • 52 Week Low
  • IRD $0.81
  • MTEN $1.81
  • 52 Week High
  • IRD $2.71
  • MTEN $9.87
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • MTEN N/A
  • Support Level
  • IRD N/A
  • MTEN N/A
  • Resistance Level
  • IRD N/A
  • MTEN N/A
  • Average True Range (ATR)
  • IRD 0.00
  • MTEN 0.00
  • MACD
  • IRD 0.00
  • MTEN 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • MTEN 0.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About MTEN Mingteng International Corporation Inc. Ordinary Shares

Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides a wide range of products including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in automobile, construction machinery, and other manufacturing industries.

Share on Social Networks: